Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$9.08 +3.9%	$7.96	$6.85 ▼ $24.76	$535.86M	-0.04	573,142 shs	370,550 shs
MNMD Mind Medicine (MindMed)	$7.79 +1.3%	$6.40	$4.70 ▼ $10.44	$588.56M	2.52	1.36 million shs	1.10 million shs
RGNX REGENXBIO	$9.61 +15.0%	$8.10	$5.04 ▼ $15.36	$482.04M	1.09	922,954 shs	1.91 million shs
SCPH scPharmaceuticals	$4.20 +2.2%	$2.81	$1.94 ▼ $5.65	$221.73M	0.36	369,543 shs	424,761 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	0.00%	+4.85%	+16.60%	+4.25%	-60.25%
MNMD Mind Medicine (MindMed)	0.00%	+8.19%	+20.59%	+14.06%	+4.99%
RGNX REGENXBIO	0.00%	+10.71%	+34.78%	+51.58%	-33.82%
SCPH scPharmaceuticals	0.00%	+18.64%	+67.33%	+43.34%	-5.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	2.1337 of 5 stars	3.5	2.0	0.0	1.9	1.7	0.6
MNMD Mind Medicine (MindMed)	2.1789 of 5 stars	3.6	1.0	0.0	3.5	0.8	0.6
RGNX REGENXBIO	4.166 of 5 stars	3.4	1.0	4.6	2.7	3.3	0.6
SCPH scPharmaceuticals	3.9474 of 5 stars	3.5	1.0	4.2	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$32.00	252.42% Upside
MNMD Mind Medicine (MindMed)	3.27	Buy	$25.50	227.34% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	229.08% Upside
SCPH scPharmaceuticals	3.00	Buy	$14.00	233.33% Upside

Current Analyst Ratings Breakdown

Latest SCPH, MNMD, RGNX, and CGEM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
4/16/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00
3/20/2025	SCPH scPharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $12.00
3/20/2025	SCPH scPharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/18/2025	RGNX REGENXBIO	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
3/17/2025	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
3/14/2025	RGNX REGENXBIO	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$22.00 ➝ $24.00

(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.61 per share	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A
RGNX REGENXBIO	$156.72M	3.08	N/A	N/A	$7.09 per share	1.36
SCPH scPharmaceuticals	$41.98M	5.28	N/A	N/A	$1.04 per share	4.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$153.16M	-$2.91	N/A	N/A	N/A	N/A	-26.54%	-25.32%	8/14/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$95.73M	-$1.29	N/A	N/A	N/A	N/A	-47.56%	-35.55%	8/12/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$3.11	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	8/7/2025 (Estimated)
SCPH scPharmaceuticals	-$54.81M	-$1.91	N/A	N/A	N/A	-264.60%	-244.93%	-68.56%	8/13/2025 (Estimated)

Latest SCPH, MNMD, RGNX, and CGEM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SCPH scPharmaceuticals	-$0.28	-$0.34	-$0.06	-$0.37	$11.63 million	$11.75 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
3/19/2025	Q4 2024	SCPH scPharmaceuticals	-$0.40	-$0.35	+$0.05	-$0.35	$12.08 million	$12.15 million
3/13/2025	Q4 2024	RGNX REGENXBIO	-$1.27	-$1.01	+$0.26	-$1.01	$23.70 million	$21.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	24.46	24.46
MNMD Mind Medicine (MindMed)	0.09	9.00	9.00
RGNX REGENXBIO	N/A	3.05	3.05
SCPH scPharmaceuticals	1.66	8.08	6.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
MNMD Mind Medicine (MindMed)	27.91%
RGNX REGENXBIO	88.08%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
MNMD Mind Medicine (MindMed)	2.45%
RGNX REGENXBIO	12.79%
SCPH scPharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.02 million	54.69 million	Optionable
MNMD Mind Medicine (MindMed)	40	75.55 million	71.68 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.04 million	Optionable
SCPH scPharmaceuticals	30	52.79 million	47.28 million	Optionable

SCPH, MNMD, RGNX, and CGEM Headlines

Recent News About These Companies

Nuveen Asset Management LLC Has $320,000 Position in scPharmaceuticals Inc. (NASDAQ:SCPH)

June 6 at 3:26 AM | marketbeat.com

BNP Paribas Financial Markets Increases Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 29, 2025 | marketbeat.com

Woodline Partners LP Sells 203,808 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

May 28, 2025 | marketbeat.com

scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025

May 22, 2025 | seekingalpha.com

Stonepine Capital Management LLC Has $2.42 Million Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 20, 2025 | marketbeat.com

Leerink Partnrs Analysts Lower Earnings Estimates for SCPH

May 20, 2025 | marketbeat.com

Suvretta Capital Management LLC Reduces Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

May 19, 2025 | marketbeat.com

scPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

May 16, 2025 | finance.yahoo.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory

May 16, 2025 | msn.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.com

Q1 2025 scPharmaceuticals Inc Earnings Call

May 16, 2025 | finance.yahoo.com

Why scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%

May 16, 2025 | aaii.com

scPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call Transcript

May 15, 2025 | seekingalpha.com

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2025 | zacks.com

scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025 | globenewswire.com

scPharmaceuticals Inc. (NASDAQ:SCPH) Stake Reduced by J. Goldman & Co LP

May 14, 2025 | marketbeat.com

Insights Ahead: scPharmaceuticals's Quarterly Earnings

May 13, 2025 | benzinga.com

scPharmaceuticals (SCPH) Expected to Announce Quarterly Earnings on Tuesday

May 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, MNMD, RGNX, and CGEM Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$9.08 +0.34 (+3.89%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$9.53 +0.45 (+4.94%)

As of 06/6/2025 05:42 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Mind Medicine (MindMed) NASDAQ:MNMD

$7.79 +0.10 (+1.30%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$7.82 +0.03 (+0.39%)

As of 06/6/2025 07:58 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

REGENXBIO NASDAQ:RGNX

$9.61 +1.25 (+14.95%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$9.70 +0.09 (+0.93%)

As of 06/6/2025 06:00 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

scPharmaceuticals NASDAQ:SCPH

$4.20 +0.09 (+2.19%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$4.19 -0.01 (-0.24%)

As of 06/6/2025 04:04 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time